Table 2.
Frequencies of different types of cutaneous adverse events per DMT
| |
Disease-modifying therapy for MS |
|
|||
|---|---|---|---|---|---|
| GA (n = 44) | SC IFN-β-1b (n = 60) | SC IFN-β-1a (n = 66) | IM IFN-β-1a (n = 59) | Total group (n = 229) | |
| Erythema |
20 (46%) |
39 (65%) |
52 (79%) |
11 (19%) |
156 (68%) |
| Lipoatrophy |
15 (34%) |
10 (17%) |
11 (17%) |
9 (15%) |
45 (20%) |
| Ecchymosis |
4 (9%) |
7 (12%) |
6 (9%) |
4 (7%) |
21 (9%) |
| Postinflammatory hyperpigmentation |
5 (11%) |
7 (11%) |
3 (5%) |
0 (0%) |
15 (7%) |
| Eczema |
1 (2%) |
8 (13%) |
4 (6%) |
1 (2%) |
14 (6%) |
| Healed ulcers |
5 (11%) |
0 (0%) |
2 (3%) |
0 (0%) |
7 (3%) |
| Urticaria |
0 (0%) |
3 (5%) |
1 (2%) |
0 (0%) |
4 (2%) |
| Necrosis |
0 (0%) |
1 (2%) |
0 (0%) |
0 (0%) |
1 (0.4%) |
| Varicose veins |
0 (0%) |
0 (0%) |
0 (0%) |
1 (2%) |
1 (0.4%) |
| Subcutaneous swelling | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) | 1 (0.4%) |
Abbreviations: DMT disease-modifying treatment, GA glatiramer acetate, IFN interferon, IM intramuscular, MS multiple sclerosis, SC subcutaneous.